TY - JOUR
T1 - Controlling release from 3D printed medical devices using CLIP and drug-loaded liquid resins
AU - Bloomquist, Cameron J.
AU - Mecham, Michael B.
AU - Paradzinsky, Mark D.
AU - Janusziewicz, Rima
AU - Warner, Samuel B.
AU - Luft, J. Christopher
AU - Mecham, Sue J.
AU - Wang, Andrew Z.
AU - DeSimone, Joseph M.
N1 - Publisher Copyright:
© 2018
PY - 2018/5/28
Y1 - 2018/5/28
N2 - Mass customization along with the ability to generate designs using medical imaging data makes 3D printing an attractive method for the fabrication of patient-tailored drug and medical devices. Herein we describe the application of Continuous Liquid Interface Production (CLIP) as a method to fabricate biocompatible and drug-loaded devices with controlled release properties, using liquid resins containing active pharmaceutical ingredients (API). In this work, we characterize how the release kinetics of a model small molecule, rhodamine B-base (RhB), are affected by device geometry, network crosslink density, and the polymer composition of polycaprolactone- and poly (ethylene glycol)-based networks. To demonstrate the applicability of using API-loaded liquid resins with CLIP, the UV stability was evaluated for a panel of clinically-relevant small molecule drugs. Finally, select formulations were tested for biocompatibility, degradation and encapsulation of docetaxel (DTXL) and dexamethasone-acetate (DexAc). Formulations were shown to be biocompatible over the course of 175 days of in vitro degradation and the clinically-relevant drugs could be encapsulated and released in a controlled fashion. This study reveals the potential of the CLIP manufacturing platform to serve as a method for the fabrication of patient-specific medical and drug-delivery devices for personalized medicine.
AB - Mass customization along with the ability to generate designs using medical imaging data makes 3D printing an attractive method for the fabrication of patient-tailored drug and medical devices. Herein we describe the application of Continuous Liquid Interface Production (CLIP) as a method to fabricate biocompatible and drug-loaded devices with controlled release properties, using liquid resins containing active pharmaceutical ingredients (API). In this work, we characterize how the release kinetics of a model small molecule, rhodamine B-base (RhB), are affected by device geometry, network crosslink density, and the polymer composition of polycaprolactone- and poly (ethylene glycol)-based networks. To demonstrate the applicability of using API-loaded liquid resins with CLIP, the UV stability was evaluated for a panel of clinically-relevant small molecule drugs. Finally, select formulations were tested for biocompatibility, degradation and encapsulation of docetaxel (DTXL) and dexamethasone-acetate (DexAc). Formulations were shown to be biocompatible over the course of 175 days of in vitro degradation and the clinically-relevant drugs could be encapsulated and released in a controlled fashion. This study reveals the potential of the CLIP manufacturing platform to serve as a method for the fabrication of patient-specific medical and drug-delivery devices for personalized medicine.
KW - 3D printing
KW - Additive manufacturing
KW - Continuous Liquid Interface Production
KW - Crosslink density
KW - Drug delivery
KW - Medical device
UR - http://www.scopus.com/inward/record.url?scp=85044585514&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85044585514&partnerID=8YFLogxK
U2 - 10.1016/j.jconrel.2018.03.026
DO - 10.1016/j.jconrel.2018.03.026
M3 - Article
C2 - 29596874
AN - SCOPUS:85044585514
SN - 0168-3659
VL - 278
SP - 9
EP - 23
JO - Journal of Controlled Release
JF - Journal of Controlled Release
ER -